diabetes diabetes mellitus
Conditions
Interventions
Baseline: 3 fasting blood samples are taken at 5 minutes interval for
measurement of:
- t=0: total IGF-I, IGF-I bioactivity, insulin, glucose
- t=5: insulin, glucose
- t=10: insulin, glucose
The t
Sponsors
Ikazia Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - age 18 * 70 years - impaired fasting glucose (IFG): fasting plasma glucose levels between 5,6 * 6,9 mmol/l (100 * 125 mg/dl) and/or impaired glucose tolerance (IGT): plasma glucose levels between 7,8 * 11,0 mmol/l (140 * 199 mg/dl) after 2 hours on the 75-g oral glucose tolerance test
Exclusion criteria
Exclusion criteria: - use of RAS inhibitors within 6 weeks prior to inclusion - use of oral glucose-lowering drugs or insulin - use of statins - use of betablockers - use of steroids, hormone replacement therapy or other study medication - contraindication for or intolerant to RAS inhibitors - untreated hypothyroidism or hyperthyroidism - negroid race - pregnancy and breastfeeding - severe renal insufficiency (GFR 5,0mmol/L)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome will be the effect of short-term administration of the angiotensin-receptor antagonist losartan on insulin sensitivity, assessed by the baseline adjusted difference in the homeostasis model assessment of insulin resistance (HOMA) at eight weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes will be the effect of short-term losartan treatment on total IGF-I and IGF-I bioactivity, and the correlation between changes in insulin sensitivity and changes in IGF-I system. | — |
Countries
Netherlands
Outcome results
None listed